Clinical Trials Logo

B-Cell Lymphoma clinical trials

View clinical trials related to B-Cell Lymphoma.

Filter by:

NCT ID: NCT04289220 Recruiting - Clinical trials for B-cell Acute Lymphoblastic Leukemia

Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia

Start date: March 15, 2020
Phase: Phase 1
Study type: Interventional

Our previous study demonstrated that anti-CD19 chimeric antigen receptor in piggyBac transposon-engineered T cells have strong tumor-killing activity in vitro and therapeutic effects in cell line-derived xenograft models, and no obvious side effects such as neurotoxicity and cytokine storm occurred. Therefore, we want to evaluate the safety and clinical effect of anti-CD19 CAR-T cells in clinical trials.

NCT ID: NCT04156243 Recruiting - B Cell Lymphoma Clinical Trials

CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies

Start date: February 1, 2018
Phase: Early Phase 1
Study type: Interventional

This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CD19 CARvac in patients with relapsed and/or refractory B cell malignancies.

NCT ID: NCT04156178 Recruiting - B Cell Lymphoma Clinical Trials

CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies

Start date: August 1, 2018
Phase: Early Phase 1
Study type: Interventional

This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CD20-CD19 cCAR in patients with relapsed and/or refractory B cell malignancies.

NCT ID: NCT04008251 Recruiting - Clinical trials for Acute Lymphoblastic Leukemia

Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies

Start date: May 27, 2019
Phase: Phase 1
Study type: Interventional

This is a single arm, open-label study to evaluate the safety and efficacy of humanized anti-CD19 CAR-T cells in patients with relapsed or refractory B cell Malignancies.

NCT ID: NCT04007978 Recruiting - Clinical trials for Acute Lymphoblastic Leukemia

Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies

Start date: August 5, 2019
Phase: Phase 1
Study type: Interventional

This is a single-center, open-label, single-arm study to evaluate the safety and efficacy of anti-CD22 CAR-T cells in patients with relapsed or refractory B-cell Malignancies.

NCT ID: NCT03999697 Recruiting - Clinical trials for Mantle Cell Lymphoma

A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies

Start date: December 1, 2018
Phase: Phase 1
Study type: Interventional

Evaluation of the efficacy and safety of CD22-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of recurrent or refractory CD22 positive B cell acute lymphoblastic leukemia (B-ALL)

NCT ID: NCT03995147 Recruiting - Lymphoma Clinical Trials

Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma

Start date: August 29, 2019
Phase: Phase 2
Study type: Interventional

This study will research untreated non-germinal center diffuse large B cell lymphoma and what causes the disease and the way patients respond to pembrolizumab combined with R-CHOP chemotherapy regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) therapy.

NCT ID: NCT03929107 Recruiting - B Cell Lymphoma Clinical Trials

Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T for Refractory/Relapsed B Cell Lymphoma.

Start date: March 28, 2019
Phase: Phase 2
Study type: Interventional

It's a single arm, open label prospective study, in which the safety and efficacy of Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T therapy are evaluated in refractory/relapsed B cell lymphoma patients.

NCT ID: NCT03881774 Recruiting - B Cell Lymphoma Clinical Trials

Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies

Start date: February 27, 2019
Phase: Phase 1
Study type: Interventional

Evaluation the safety and efficacy of cord blood-derived CAR-T cells in patients with relapsed/refractory B cell leukemia/lymphoma whose disease relapsed after autologous CAR-T cells therapy or who fail to preparation for autologous CAR-T cells

NCT ID: NCT03854994 Recruiting - Clinical trials for B-cell Acute Lymphoblastic Leukemia

CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia

Start date: August 1, 2018
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to evaluate the safety and clinical activity of anti-CD19 Chimeric Antigen Receptor T cells (KD-019 CAR-T)infusion in the treatment of relapsed/refractory B-cell Lymphoma and B-cell acute lymphoblastic leukemia (B-ALL).